G. Curigliano

377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

S.A. Hurvitz, Shanu Modi, Wěi Li et al. · Annals of Oncology · 2023 · 58 citations · Full text

Medicine, Oncology, Breast Oncology +15

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

S.S. Shachar, G. Curigliano, F.P. Duhoux et al. · UNC Libraries · 2021 · 29 citations · Full text

Medicine, Oncology, Pharmacology +12

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

P.L. Bedard, C. Anders, Naiheng Lin et al. · UNC Libraries · 2021 · 22 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy

Andrea Botticelli, S. Scagnoli, PierFranco Conte et al. · Annals of Oncology · 2024 · 19 citations

Medicine, Molecular Medicine, Oncology +14

291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)

N. Harbeck, S. Modi, L. Pusztai et al. · Annals of Oncology · 2025 · 12 citations

Medicine, Oncology, Pharmacology +14